The purpose of this project was to assess the concurrent and predictive validity of the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) for military service members undergoing substance abuse treatment. Concurrent validity was assessed by examining the correlation of SOCRATES subscales with subscales from the Addiction Treatment Attitude Questionnaire. Predictive validity was assessed by examining the ability of SOCRATES subscales to predict length of stay in treatment and successful completion of treatment. Scores on the SOCRATES were correlated in the expected direction with scores on the Addiction Treatment Attitude Questionnaire and predicted length of stay in treatment and successful completion of treatment. The findings provide support for the validity of the SOCRATES with substance abuse treatment-seeking military service members.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7205/milmed.171.9.900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congenital Factor VII Deficiency: A Case Study of Four Family Members.
Cureus
December 2024
Hematology, Avicenna Military Hospital, Marrakesh, MAR.
Congenital factor VII (FVII) deficiency is a rare genetic disorder with autosomal recessive inheritance, characterized by molecular and clinical heterogeneity. This article reports four Moroccan cases of FVII deficiency within the same family, two of which were associated with Gilbert's syndrome. The index case was a 15-year-old girl with a history of menorrhagia and jaundice.
View Article and Find Full Text PDFTransanal Resection of a Prolapsed Rectal Lipoma: A Report of a Rare Case.
Cureus
January 2025
College of Medicine, King Saud University, Riyadh, SAU.
Lipoma is a benign tumor that arises from mesenchymal cells and is considered relatively rare. Although lipomas can develop anywhere in the digestive tract, they are seldom found within the intestinal tract. Typically asymptomatic, colonic lipomas usually do not require treatment unless they result in symptoms that warrant surgical intervention.
View Article and Find Full Text PDFImproving the Predictive Strength of Better-Ear Four-Frequency Pure-Tone Average With the Addition of the Tinnitus and Hearing Survey-Hearing Subscale.
Ear Hear
January 2025
Audiology and Speech Pathology Center, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Objectives: The objective of this project was to quantify the relative efficacy of a four-frequency pure-tone average in the better ear (PTA4), the Hearing subscale of the Tinnitus and Hearing Survey (THS-H), and a combination of the two in predicting speech-in-noise performance, hearing aid recommendation, and hearing aid use among United States service members (SMs).
Design: A two-analysis retrospective study was performed. The first analysis examined the degree to which better-ear PTA4 alone, THS-H alone, and better-ear PTA4 in conjunction with THS-H predicted performance on a speech-in-noise test, the modified rhyme test.
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial.
Lancet Microbe
January 2025
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Background: Although existing COVID-19 vaccines are known to be highly effective against severe disease and death, data are needed to assess their ability to reduce SARS-CoV-2 infection. We aimed to estimate the efficacy of the NVX-CoV2373 protein subunit vaccine against SARS-CoV-2 infection, regardless of symptoms, among adolescents.
Methods: We performed an ancillary observational study (SNIFF) to the phase 3, observer-blinded, randomised, placebo-controlled PREVENT-19 trial that assessed vaccine efficacy against symptomatic COVID-19 in the USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!